Aclaris Therapeutics(ACRS)_个股概要_股票价格_最新资讯_行情走势_历史数据

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ACRS Aclaris Therapeutics

未开盘 05-01 16:00:00 EDT

1.26

+0.05

+4.13%

盘后1.26

+0.000.00%

16:01 EDT

最高1.27	最低1.21	成交量97.91万
今开1.21	昨收1.21	日振幅5.37%
总市值8,979万	流通市值6,392万	总股本7,126万
成交额121.64万	换手率1.93%	流通股本5,073万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"ACRS","market":"US","secType":"STK","nameCN":"Aclaris Therapeutics","latestPrice":1.26,"timestamp":1714593600000,"preClose":1.21,"halted":0,"volume":979115,"hourTrading":{"tag":"盘后","latestPrice":1.26,"preClose":1.26,"latestTime":"16:01 EDT","volume":1972,"amount":2484.72,"timestamp":1714593714323},"delay":0,"floatShares":50727557,"shares":71264786,"eps":-1.27,"marketStatus":"未开盘","marketStatusCode":0,"change":0.05,"latestTime":"05-01 16:00:00 EDT","open":1.21,"high":1.27,"low":1.205,"amount":1216375.125915,"amplitude":0.053719,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.27,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1714636800000},"adr":0,"listingDate":1444190400000,"adjPreClose":1.21,"adrRate":0,"postHourTrading":{"tag":"盘后","latestPrice":1.26,"preClose":1.26,"latestTime":"16:01 EDT","volume":1972,"amount":2484.72,"timestamp":1714593714323},"volumeRatio":0.960578},"requestUrl":"/m/hq/s/ACRS","defaultTab":"news","newsList":[{"id":"2412733136","title":"Aclaris Therapeutics Inc    预计每股亏损 34 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2412733136","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2412733136?lang=zh_cn&edition=full","pubTime":"2024-02-19 22:06","pubTimestamp":1708351568,"startTime":"0","endTime":"0","summary":"   * Aclaris Therapeutics Inc    预计将在2月21日公布截至2023年12月31日的业绩报告时显示季度收入下降(预计)    * 根据LSEG的数据，8位分析师的平均预期显示，这家总部位于宾夕法尼亚州韦恩市的公司预计营收将从去年同期的775万美元下降56.6%，至336.3万美元。* LSEG 分析师对 Aclaris Therapeutics Inc 的平均预期是每股亏损 34 美分。* 华尔街对 Aclaris Therapeutics Inc 的 12 个月目标价中位数为 2.00 美元，高于其上一次收盘价 1.19 美元。2月19日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2404899463","title":"BUZZ--美国股票走势-Halozyme、Scorpio Tankers、AMD(超威/超微)","url":"https://stock-news.laohu8.com/highlight/detail?id=2404899463","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2404899463?lang=zh_cn&edition=full","pubTime":"2024-01-17 00:02","pubTimestamp":1705420962,"startTime":"0","endTime":"0","summary":"        *      个股走势的 Eikon 搜索字符串：[STXBZ］        *      The Day Ahead 新闻通讯：          *      The Morning News Call时事通讯：      1月16日 - 华尔街主要股指周二下跌，原因是高盛和摩根士丹利的财报喜忧参半，令投资者对资本市场和交易的健康状况持谨慎态度，银行股因此承压，而特斯拉和苹果的下跌也对股指造成了影响。美东时间 10:37，道琼斯工业平均指数  下跌 0.37%，报 37,452.44 点。标普500指数  和纳斯达克综合指数  下跌0.11%，报14,956.264点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2403786905","title":"BUZZ-Aclaris Therapeutics 启动战略业务审查","url":"https://stock-news.laohu8.com/highlight/detail?id=2403786905","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2403786905?lang=zh_cn&edition=full","pubTime":"2024-01-16 21:27","pubTimestamp":1705411639,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    1月16日 - ** Aclaris Therapeutics   股价盘前上涨9.3%至1.01美元** ACRS表示，\"公司正在对其业务进行战略审查，以确定如何优化资本配置，实现股东回报最大化\"。** 在道格拉斯-马尼恩（Douglas Manion）卸任后，公司董事长兼前首席执行官尼尔-沃克（Neal Walker）被任命为 (link) 临时首席执行官。** 该公司的特应性皮炎药物 (link) 在一项中期试验中未显示出统计学意义。** 2023 年公司股价下跌 93.3","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2402473384","title":"BUZZ--美国股票走势-美国航空公司、石油公司、Salesforce","url":"https://stock-news.laohu8.com/highlight/detail?id=2402473384","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2402473384?lang=zh_cn&edition=full","pubTime":"2024-01-11 22:13","pubTimestamp":1704982434,"startTime":"0","endTime":"0","summary":"        *      个股异动的 Eikon 搜索字符串：[STXBZ］        *      The Day Ahead 新闻通讯：          *      The Morning News Call时事通讯：      1月11日 - 追踪华尔街主要指数的期货周四转为负面，因为消费者通胀率高于预期，抑制了提前开始降息的预期。美东时间9:01，道指电子盘  下跌0.23%，报37847点。标普500指数小型股  下跌0.24%，报4,808.75点；纳斯达克100指数小型股  下跌0.16%，报16,917.5点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2402429928","title":"BUZZ-皮炎药物试验受挫，BTIG 将 Aclaris 的评级下调至 \"中性\"。","url":"https://stock-news.laohu8.com/highlight/detail?id=2402429928","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2402429928?lang=zh_cn&edition=full","pubTime":"2024-01-11 20:29","pubTimestamp":1704976144,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    1月11日 - ** 药物开发商Aclaris Therapeutics   股价盘前下跌3.8%至97美分** 券商BTIG将该公司股票评级从 \"买入 \"下调至 \"中性\"** 该公司周三报告说 (link)，在一项中期试验的第二部分中，其特异性皮炎日服一次型药物没有显示出统计学意义** 特应性皮炎会引起瘙痒，导致皮肤发红、肿胀和皲裂** 每日两","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2402410329","title":"BUZZ-皮炎药物 Aclaris 在中期试验受挫后下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2402410329","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2402410329?lang=zh_cn&edition=full","pubTime":"2024-01-10 20:40","pubTimestamp":1704890419,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    1月10日 - ** Aclaris Therapeutics   股价盘前下跌约10%至1.15美元** 该公司称， (link)，在一项中期试验中，其特应性皮炎药物的每日一次版本未显示出统计学意义。** 补充说，每日两次的版本达到了试验的主要目标** 特应性皮炎会引起瘙痒，导致皮肤发红、肿胀和皲裂 ** 2023 年股价下跌 93.3","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2383032266","title":"BUZZ-Aclaris放弃类风湿性关节炎药物开发，创历史新低","url":"https://stock-news.laohu8.com/highlight/detail?id=2383032266","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2383032266?lang=zh_cn&edition=full","pubTime":"2023-11-14 00:09","pubTimestamp":1699891742,"startTime":"0","endTime":"0","summary":"(更新)    11月13日 - ** Aclaris Therapeutics公司股价  下跌86.9%，创下62美分的历史新低** 该公司表示，由于在一项中期试验中未能达到主要或次要目标，它将停止开发其类风湿性关节炎药物zunsemetinib的 。** 在12周的疗效评估中，zunsemetinib和安慰剂之间没有明显差异 - co** 券商 BTIG 将 PT 值从 29 美元下调至 8 美元** 安慰剂治疗组的表现优于大多数其他晚期类风湿关节炎试验，而且zunsemetinib治疗组的停药率出乎意料地高，因此研究结果令人大吃一惊 - BTIG** 股价今年以来下跌~96","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2383087630","title":"更新版 1-Aclaris Therapeutics 将停止开发类风湿关节炎药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2383087630","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2383087630?lang=zh_cn&edition=full","pubTime":"2023-11-13 20:17","pubTimestamp":1699877825,"startTime":"0","endTime":"0","summary":"(第2和第3段增加了细节，第4段增加了股份)    路透11月13日 - Aclaris Therapeutics   周一表示，在一项中期试验失败后，公司将停止开发类风湿关节炎治疗药物。     该公司表示，在12周的疗效评估中，该药物zunsemetinib与安慰剂之间没有明显差异。     该公司还将停止正在进行的一项研究银屑病关节炎的中期试验的入组。     公司股票在开盘前停牌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aclaristx.com","stockEarnings":[{"period":"1week","weight":0.0769},{"period":"1month","weight":0},{"period":"3month","weight":0.05},{"period":"6month","weight":-0.7654},{"period":"1year","weight":-0.8592},{"period":"ytd","weight":0.2}],"compareEarnings":[{"period":"1week","weight":-0.01},{"period":"1month","weight":-0.0418},{"period":"3month","weight":0.0228},{"period":"6month","weight":0.1511},{"period":"1year","weight":0.2179},{"period":"ytd","weight":0.0527}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Aclaris Therapeutics, Inc.于2012年7月在美国特拉华州成立。该公司是一家临床阶段的生物制药公司，专注于开发免疫炎症疾病的新型候选药物。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.159429},{"month":2,"riseRate":0.444444,"avgChangeRate":-0.00511},{"month":3,"riseRate":0.444444,"avgChangeRate":-0.035243},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.000298},{"month":5,"riseRate":0.555556,"avgChangeRate":-0.033401},{"month":6,"riseRate":0.625,"avgChangeRate":-0.011266},{"month":7,"riseRate":0.5,"avgChangeRate":-0.024457},{"month":8,"riseRate":0.5,"avgChangeRate":-0.042275},{"month":9,"riseRate":0.5,"avgChangeRate":0.038413},{"month":10,"riseRate":0.25,"avgChangeRate":0.052818},{"month":11,"riseRate":0.222222,"avgChangeRate":-0.060376},{"month":12,"riseRate":0.777778,"avgChangeRate":0.149317}],"exchange":"NASDAQ","name":"Aclaris Therapeutics","nameEN":"Aclaris Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aclaris Therapeutics(ACRS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Aclaris Therapeutics(ACRS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Aclaris Therapeutics,ACRS,Aclaris Therapeutics股票,Aclaris Therapeutics股票老虎,Aclaris Therapeutics股票老虎国际,Aclaris Therapeutics行情,Aclaris Therapeutics股票行情,Aclaris Therapeutics股价,Aclaris Therapeutics股市,Aclaris Therapeutics股票价格,Aclaris Therapeutics股票交易,Aclaris Therapeutics股票购买,Aclaris Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aclaris Therapeutics(ACRS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Aclaris Therapeutics(ACRS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}

公司概况